



MEN'S FORMULA

A natural solution for supporting prostate health.



For all men over 40, prostate health should be an important issue. Infinity2 Men's Formula is a natural solution to support prostate health. This formulation supplies a highly effective blend of potent herbs, vitamins, minerals, amino acids, and antioxidants to help maintain normal urinary flow, increase testicular function, encourage optimal prostate health and potentially enhance sexual desire and performance. At the heart of Infinity2 Men's Formula is CAeDS®, an exclusive nutrient delivery system that guarantees maximum effectiveness.

I need Men's Formula if...

- I am a male over age 40.
- I want extra support for prostate health.
- My doctor has recommended a natural prostate formula.
- Prostate symptoms are affecting my sexual performance.

Recommended Usage:
Take 2 capsules daily on an empty stomach.

Storage:
Store closed in a cool, dry location.

Shelf Life:
2 years

Item#: US60456
Men's Formula 60 count



Benefits:

- Promotes prostate health.
- Helps maintain normal urinary flow and testicular function.
- Encourages healthy sexual desire and performance.

What Makes Men's Formula Superior?

Infinity2's Men's Formula naturally and effectively supports optimal prostate health.

- Contains a patented form of zinc, zinc arginine chelate, to ensure this important mineral is delivered to the cells of the prostate.
- Provides a proprietary blend of herbs clinically proven to promote prostate health.
- Includes a proprietary blend of protease enzymes to help combat the inflammation associated with prostate disorders.
- Includes a custom-formulated Chelate Activated Enzyme Delivery System (CAeDS®) ensuring the nutrients in this supplement are delivered to the cells of the body for guaranteed maximum effectiveness.
- Natural, highest quality ingredients, and completely vegetarian.
- Contains no lactose, gluten, MSG, salt, sugar, artificial colors, flavors or chemical preservatives, additives or fillers.

Allergens:

Contains no major allergens.
(Contains no milk, egg, wheat, soy, peanuts, nuts, corn, fish or shellfish.)

Drug/Nutrient Interactions:

Do not use this product if you are taking blood thinning medications such as warfarin or coumadin, except under the direction of a physician. If you are taking medications, consult with your physician or pharmacist.

Special Considerations/Contraindications:

Not recommended for pregnant or nursing women and should not be used by those individuals with bleeding disorders.

If you have an elevated PSA (Prostate Specific Antigen) level or prostate cancer, consult with your personal physician before using this product.



HEARTLAND
select

Supplement Facts

Serving Size 2 Capsules
Servings Per Container 30

Amount Per Serving		% DV
Vitamin D	1066 IU	266%
Vitamin B6	120 mg	6000%
Zinc (as zinc arginine amino acid chelate and zinc chelazome®)	8.5 mg	57%
Selenium (as selenium amino acid chelate)	260 mcg	371%
Manganese (as manganese chelazome®)	0.16 mg	8%
Saw Palmetto (berries)	200 mg	†
Pygeum (bark) Extract	66 mg	†
Men's Formula Proprietary Blend	349 mg	†
Selenium Amino Acid Chelate, Quercetin, Zinc Arginine Amino Acid Chelate, Zinc Chelazome®, Glucoamylase, Magnesium Chelazome®, Lipase, Manganese Chelazome®, Protease 6.0, Bromelain, Papain.		
CAeDS® for Men's Formula	46 mg	†
Pectinase, Cellulase, Amylase, CereCalase®, Calcium Amino Acid Chelate, Zinc Chelazome®, Glucoamylase, Magnesium Chelazome®, Lipase, Manganese Chelazome®, Protease 4.5.		

† Daily Value not established.

Other ingredients: Vegetable fiber, water.

Albion International, Inc. patent 5882685.
© 2008 Heartland Select

60705-60456

Formulated by Infinity2 Health Sciences, Inc.

Infinity2 High Potency Technical Information

The Prostate

The prostate gland is a chestnut shaped organ that surrounds a portion of the urethra in the male. The gland is responsible for manufacturing and secreting milky fluid (semen) into the urethra combining with sperm at the time of ejaculation. Disorders of the prostate commonly increase after age of 40. Some of the most common conditions include prostatitis (prostate inflammation), benign prostatic hyperplasia or BPH (prostate enlargement), and prostate cancer. Typically, diseases of the prostate will cause symptoms of bladder outlet obstruction resulting in urinary frequency, painful urination, incomplete bladder emptying and sexual dysfunction.

Recent research has focused on the associations between nutrition and prostate health. A number of dietary factors have been found to affect prostate health. Reducing saturated fat intake, increasing the intake of omega-3 fatty acids, increasing fiber intake, increasing dietary antioxidants from fruits and vegetables, and including soy foods all appear to promote prostate health and decrease the risk of prostate cancer. Evidence is also accumulating that supports the possible roles of specific nutrients and herbs in protecting prostate health. Nutrients and herbs that appear to have the greatest potential in promoting prostate health include saw palmetto, pygeum, nettles, zinc, arginine, vitamin D and antioxidant nutrients such as selenium, vitamin E and lycopenes (13; 44).

Saw Palmetto

Saw Palmetto (*Serenoa Repens*) is a dwarf palm that grows to be 6 to 10 feet tall, and can be found in the southeastern United States. Native Americans have long used saw palmetto berries as an invigorating tonic for the entire genitourinary system. Today, saw palmetto berries are one of the most well-researched natural remedies for prostate disorders. In several studies Saw Palmetto was shown to be as effective as commonly used prostate medications (Finasteride and Tamsulosin) without the negative side effects that impact male sexual function typically occurring with these medications (11; 19; 22; 50; 57; 61). Numerous studies have shown that saw palmetto statistically improves urinary symptoms associated with benign prostatic enlargement (BPH). (2; 8; 27; 28; 41; 48; 56; 61). Saw palmetto is currently being researched for its potential benefits for prostate cancer (3; 12; 29; 31; 33).

Pygeum

Pygeum africanum is an evergreen species found across the entire continent of Africa. South African tribes have used Pygeum bark for centuries to soothe bladder discomfort and treat "old man's disease" (54), and it has been used in Europe since the 1960s to treat men suffering from BPH (34). Numerous studies have demonstrated the benefit of pygeum in improving the urinary symptoms of BPH without side effects or adverse reactions (9; 14; 35; 37; 60). Although early research indicates that Pygeum does not appear to reduce the size of the prostate (62), Pygeum does clearly improve the symptoms of BPH by modulating bladder contractility (4), providing anti-inflammatory benefits (47), increasing beneficial testosterone secretion, and restoring secretory activity of prostate cells (4; 62).

Nettles

The use of stinging nettle (*Urtica dioica*) has its origins in Indian medical history, where it was used to relieve the stinging, prickling sensations of prostate infection and enlargement. A few recent published studies have demonstrated beneficial effects of stinging nettle for the symptoms of BPH, both alone (51) and in combination with pygeum or saw palmetto (37; 40; 43; 55).

Zinc, Arginine and Prostate Health

The concentration of zinc in the prostate gland is much higher than in other human tissues. This fact, in combination with the epidemiological evidence has led researchers to investigate the potential roles of zinc in prostate health. Zinc has been reported to interfere with the conversion of testosterone to DHT, thereby preventing prostate enlargement (23; 25; 38). A few studies have shown that zinc therapy may reduce the size of the prostate (25). Researchers have also discovered that zinc possesses a specific regulatory mechanism to help control cancer cell proliferation (26; 58). In prostate cancer, the cancer cells undergo a metabolic transformation from zinc-accumulating, citrate-producing cells to citrate-oxidizing, malignant cells that lose the ability to accumulate zinc (16-18).

80% of seminal fluid is composed of the amino acid arginine and researchers have found that the addition of arginine to zinc supplementation may provide additional benefits for prostatitis (25). Infinity2's Men's Formula uses a unique patented form of zinc bound to arginine. Zinc arginine chelate has been shown to have a greater ability to reach the male gonadal tissues than other forms of zinc (30).

Selenium

Selenium works along with vitamin E and other antioxidants, such as quercetin, to help reduce the effects of free radical oxidation (59). Several studies have found that selenium supplementation may reduce the incidence and/or recurrence of prostate cancer (15; 24; 49). In one study published in the British Journal of Urology (15), the authors concluded that selenium treatment was associated with a 63% reduction in prostate cancer recurrence in 974 men with a history of the disease.

Selenium and vitamin E are being researched for their potential role in reducing the risk of prostate cancer (36). Selenium and quercetin may down-regulate (slow the growth of) prostate cell proliferation (45).

Lycopenes

Lycopene's unique structure and biologic properties make it a potent antioxidant. This may partially explain why the dietary intake of lycopene-rich foods such as tomatoes are associated with lower risk of prostate cancer (5). Several studies have examined lycopene alone and in combination with other nutrients to support prostate health (52). One such study found that the combination of lycopene and vitamin E treatment suppressed the growth of prostate cancer cells (39). Taking lycopene supplements has been found to slow the growth of tumors and lower PSA scores in men with prostate cancer (53).



Guaranteed nutrient delivery™



HEARTLAND
select

Men's Formula Technical Information (Continued)

Vitamin D

Several studies show a link between sun exposure and reduced risk of prostate cancer. Men with genetic variations that decrease their vitamin D levels are at increased risk of developing the disease. This could help to explain why African Americans, whose dark skin does not absorb as much UVB radiation to allow the skin to produce Vitamin D, are at increased risk compared to Caucasians. The mechanism is still being studied, but it appears vitamin D levels influence a substance called insulin-like growth factor 1 (IGF-1).

Preliminary research examining the role of Vitamin D in prostate health seems to indicate that supplementation with vitamin D may be beneficial in improving pain scores, maintaining strength, and improving quality of life for those with prostate cancer (46).

Proprietary Enzyme Blend

Inflammation plays a key role in the development of prostate conditions and the effects of aging. To help address this issue, Infinity2 Men's Formula includes a proprietary blend of protease enzymes including bromelain, papain and protease. Protease enzymes break down large protein molecules into smaller proteins and amino acids that promote healing and reduce inflammation (6; 7; 10). Bromelain is particularly beneficial in cases of inflammation. Bromelain is a special combination of protease enzymes derived from pineapples. In addition to its general protease effects, bromelain has been shown to modulate the chemical messengers of the immune system (cytokines and prostaglandins) (1; 20; 21; 32; 42). By modulating the activity of specific chemical messengers (cytokines and prostaglandins) that are associated with pain and inflammation, bromelain may exert specific anti-inflammatory and anti-edema effects.

Infinity2 Men's Formula

Infinity2's specially formulated Men's Formula not only includes saw palmetto, but also provides other potent herbs, vitamins, minerals, amino acids and antioxidants that have been clinically proven to promote a healthy prostate. The Infinity2 formulation team has combined these important nutrients and herbs with a proprietary blend of protease enzymes to create the most effective product available for complete prostate support. At the heart of Infinity2 Men's Formula is CAeDS®, an exclusive nutrient delivery system that guarantees maximum effectiveness.

The CAeDS® Difference

CAeDS® is a highly sophisticated nutrient delivery system that ensures the rich nutrients in Infinity2 products are absorbed and delivered to the cells of the body. The powerful combination of Infinity2's premium quality ingredients, advanced formulations, and a cellular nutrient delivery system makes it virtually impossible for any other nutritional product to match the effectiveness of our products. Simply put, CAeDS® guarantees maximum effectiveness!



Guaranteed nutrient delivery™



HEARTLAND
select

Reference List

1. Monograph:Bromelain. *Altern Med Rev* 3: 302-305, 1998.
2. Al-Shukri SH, Deschaseaux P, Kuzmin IV and Amdiy RR. Early urodynamic effects of the lipido-sterolic extract of *Serenoa repens* (Permixon®) in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. *Prostate Cancer Prostatic Dis* 3: 195-199, 2000.
3. Anderson ML. A preliminary investigation of the enzymatic inhibition of Salpha-reduction and growth of prostatic carcinoma cell line LNCaP-HCG by natural astaxanthin and Saw Palmetto lipid extract in vitro. *J Herb Pharmacother* 5: 17-26, 2005.
4. Andro MC and Riffaud JP. Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience. *Curr Ther Res* 56: 796-817, 1995.
5. Ansari MS and Ansari S. Lycopene and prostate cancer. *Future Oncol* 1: 425-430, 2005.
6. Bergkvist R. The proteolytic enzymes of *Aspergillus oryzae* II: properties of the proteolytic enzymes. *Acta chemie Scandnavia* 17: 1541-1551, 1963.
7. Bergkvist R and Svare PO. Studies on the thrombolytic effect of a protease from *Aspergillus oryzae*. *Acta Physiologie Scandnavia* 60: 363-371, 1964.
8. Boyle P, Robertson C, Lowe F and Roehrborn C. Updated meta-analysis of clinical trials of *Serenoa repens* extract in the treatment of symptomatic benign prostatic hyperplasia. *BJU Int* 93: 751-756, 2004.
9. Breza J, Dzuryn O, Borowka A, Hanus T, Petrik R, Blane G and Chadha-Boreham H. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. *Curr Med Res Opin* 14: 127-139, 1998.
10. Buccì LR and Stiles JC. Sports injuries and proteolytic enzymes. *Today's Chiropractor* 16: 31, 1987.
11. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di SE, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A and Perrin P. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1,098 patients. *Prostate* 29: 231-240, 1996.
12. Chan JM, Elkik EF, Silva SJ, Broering JM, Latini DM and Carroll PR. Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer. *Urology* 66: 1223-1228, 2005.
13. Chan JM, Gann PH and Giovannucci EL. Role of diet in prostate cancer development and progression. *J Clin Oncol* 23: 8152-8160, 2005.
14. Chatelein C, Autet W and Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. *Urology* 54: 473-478, 1999.
15. Clark LC, Dalkin B, Krongrad A, Combs GF Jr., Turnbull BW, Slate EH, Witherington R, Herlong JH, Janosko E, Carpenter D, Borosso C, Falk S and Rounder J. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. *Br J Urol* 81: 730-734, 1998.
16. Costello LC, Feng P, Milon B, Tan M and Franklin RB. Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. *Prostate Cancer Prostatic Dis* 7: 111-117, 2004.
17. Costello LC and Franklin RB. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. *Prostate* 35: 285-296, 1998.
18. Costello LC, Franklin RB and Feng P. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. *Mitochondrion* 5: 143-153, 2005.
19. Debruyne F, Koch G, Boyle P, Da Silva FC, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R and Raynaud JP. Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study. *Eur Urol* 41: 497-506, 2002.
20. Desser L, Rehberger A, Kokkon E and Paukovits W. Cytokine synthesis in human peripheral blood mononuclear cells after oral administration of polyenzyme preparations. *Oncology* 50: 403-407, 1993.
21. Desser L, Rehberger A and Paukovits W. Proteolytic enzymes and amylase induce cytokine production in human peripheral blood mononuclear cells in vitro. *Cancer Biother* 9: 253-263, 1994.
22. Di SE, Monti S, Sciarra A, Varasano PA, Martini C, Lanzara S, D'Eramo G, Di NS and Toscano V. Effects of long-term treatment with *Serenoa repens* (Permixon) on the concentration, and regional distribution of androgens and epidermal growth factor in benign prostatic hyperplasia. *Prostate* 37: 77-83, 1998.
23. Dutkiewicz S. Zinc and magnesium serum levels in patients with benign prostatic hyperplasia (BPH) before and after prozin therapy. *Mater Med Pol* 27: 15-17, 1995.
24. Eminian M, FitzGerald JM, Gleave M and Chambers K. Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. *Cancer Causes Control* 16: 1125-1131, 2005.
25. Fahim MS, Wang M, Sutcu MF and Fahim Z. Zinc arginate, a 5 alpha-reductase inhibitor, reduces rat ventral prostate weight and DNA without affecting testicular function. *Andrologia* 25: 369-375, 1993.
26. Feng P, Li TL, Guan ZX, Franklin RB and Costello LC. Direct effect of zinc on mitochondrial apoptosis in prostate cells. *Prostate* 52: 311-318, 2002.
27. Gerber GS. Saw palmetto for the treatment of men with lower urinary tract symptoms. *J Urol* 163: 1408-1412, 2000.
28. Gerber GS, Kuznetsov D, Johnson BC and Burstein JD. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. *Urology* 56: 969-974, 2001.
29. Goldmann WJ, Sharma AL, Currier SJ, Johnson PD, Rana A and Sharma CP. Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. *Cell Biol Int* 25: 1117-1124, 2001.
30. Graffl D. J. Zinc Arginine Amino Acid Chelate. 2006. Ref Type: Unpublished Work
31. Habib FK, Ross M, Ho CK, Lyons V and Chapman K. *Serenoa repens* (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. *Int J Cancer* 114: 190-194, 2005.
32. Hale J, Greer PK and Sempowski GD. Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. *Cell Immunol* 104: 183-190, 2002.
33. Hill B and Kyrianiou N. Effect of permixon on human prostate cell growth: lack of apoptotic action. *Prostate* 61: 73-80, 2004.
34. Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. *Prostate Suppl* 3: 1-7, 1990.
35. Ishani A, MacDonald R, Nelson D, Rutks J and Witt TJ. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. *Am J Med* 109: 654-664, 2004.
36. Klein EA. Selenium and vitamin E cancer prevention trial. *Ann NY Acad Sci* 1031: 234-241, 2004.
37. Krzeski T, Kazon M, Borkowski A, Witek A and Kuczera J. Combined extracts of *Urtica dioica* and *Pygeum africanum* in the treatment of benign prostatic hyperplasia: double-blind comparison of two doses. *Clin Ther* 15: 1011-1020, 1993.
38. Leake A, Chisholm GD and Habib FK. The effect of zinc on the 5 alpha-reduction of testosterone by the hyperplastic human prostate gland. *J Steroid Biochem* 20: 651-655, 1984.
39. Limpens J, Schroeder FH, de Ridder CM, Bolder CA, Wildhagen MF, Obermuller-Jevic UC, Kramer K and van Weerden WM. Combined lycopene and vitamin E treatment suppresses the growth of PC-3a6C human prostate cancer cells in nude mice. *J Nutr* 136: 1287-1293, 2006.
40. Lopatkin N, Sivkov A, Walther C, Schlafke S, Medvedev A, Avdeichuk J, Golubev G, Melnik K, Elenberger N and Engelmann U. Long-term efficacy and safety of a combination of sabal and urtica extract for lower urinary tract symptoms—a placebo-controlled, double-blind, multicenter trial. *World J Urol* 23: 139-146, 2005.
41. Lupton LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, Chan TL, Dorey FJ, Garris JB, Veltri RW, Santos PB, Stonebrook KA and deKernion JB. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. *J Urol* 163: 1451-1456, 2000.
42. Maurer HR. Bromelain: biochemistry, pharmacology and medical use. *Cell Mol Life Sci* 58: 1234-1245, 2001.
43. Melo EA, Bertero EB, Rios LA and Mattos D, Jr. Evaluating the efficiency of a combination of Pygeum africanum and sting nettle (*Urtica dioica*) extracts in treating benign prostatic hyperplasia (BPH): double-blind, randomized, placebo controlled trial. *Int Braz J Urol* 28: 418-425, 2002.
44. Meyer F, Galan P, Douville F, Bairati I, Kegel P, Bertrais S, Estuquio C and Herberg S. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SUJ.VMAX trial. *Int J Cancer* 116: 182-186, 2005.
45. Morris DJ, Pramanik R, Zhang X, Carey AM, Ragavan N, Martin FL and Muir GH. Selenium- or quercetin-induced retardation of DNA synthesis in primary prostate cells occurs in the presence of a concomitant reduction in androgen-receptor activity. *Cancer Lett* 239: 111-122, 2006.
46. Nelson WC, De Marzo AM, DeVlase TL and Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. *J Urol* 172: 56-511; discussion S11-12, 2004.
47. Paubert-Braquet M, Cave A, Hocquemiller R, Delacroix D, Dupont C, Hedef N and Borgeat P. Effect of Pygeum africanum extract on A23187-stimulated production of lipoxigenase metabolites from human polymorphonuclear cells. *Lipid Mediat Cell Signal* 9: 285-290, 1994.
48. Pytel YA, Vinarov A, Lopatkin N, Sivkov A, Gorilovsky L and Raynaud JP. Long-term clinical and biologic effects of the lipido-sterolic extract of *Serenoa repens* in patients with symptomatic benign prostatic hyperplasia. *Adv Ther* 19: 297-306, 2002.
49. Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. *Proc Nutr Soc* 64: 527-542, 2005.
50. Rhodes L, Primka RL, Berman C, Vergult G, Gabriel M, Pierre-Malice M and Gibelin B. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in vitro and in vivo 5 alpha reductase inhibition. *Prostate* 22: 49-51, 1993.
51. Safarinejad MR. *Urtica dioica* for Treatment of Benign Prostatic Hyperplasia: Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study. *J Herb Pharmacother* 5: 1-11, 2005.
52. Santillo VM and Lowe FC. Role of vitamins, minerals and supplements in the prevention and management of prostate cancer. *Int Braz J Urol* 32: 3-14, 2006.
53. Schroeder FH, Bosh ML, Boeve EB, de MR, Zuidgeest-van Leeuwen SD, Kersten I, Wildhagen MF and van HA. Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: effectiveness of a dietary supplement. *Eur Urol* 48: 922-930, 2005.
54. Simons AJ, Dawson IK, Dugumba B and Tchoundjeu Z. Passing probes: prostate and prunus. *HerbalGram* 43: 49-53, 1998.
55. Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. *BJU Int* 86: 439-442, 2000.
56. Sponovan VN, Sniakovska LA, Sarrazin B and Raynaud JP. Efficacy and tolerability of the lipido-sterolic extract of *Serenoa repens* (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens. *Adv Ther* 16: 231-241, 1999.
57. Strauch G, Perles P, Vergult G, Gabriel M, Gibelin B, Cummings S, Malbecq V and Malice MP. Comparison of finasteride (Proscar) and *Serenoa repens* (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteers. *Eur Urol* 26: 247-252, 1994.
58. Tsui KH, Chang PL and Juang HH. Zinc blocks gene expression of mitochondrial acetonide in human prostatic carcinoma cells. *Int J Cancer* 118: 609-615, 2006.
59. Venkateswaran V, Flesher NE and Klotz LH. Synergistic effect of vitamin E and selenium in human prostate cancer cell lines. *Prostate Cancer Prostatic Dis* 7: 54-56, 2004.
60. Witt TJ, Ishani A, Mac DR, Rutks J and Stark G. Pygeum africanum for benign prostatic hyperplasia. *Cochrane Database Syst Rev* CD001044, 2002.
61. Witt TJ, Ishani A, Stark G, MacDonald R, Lau J and Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. *JAMA* 280: 1604-1609, 1998.
62. Yoshimura Y, Yamaguchi O, Bellamy F and Constantinou CE. Effect of Pygeum africanum tadenan on micriturion and prostate growth of the rat secondary to coadministered treatment and post-treatment with dihydrotestosterone. *Urology* 61: 474-478, 2003.